肿瘤细胞治疗研究
英文原题：Elimination of residual adult T-cell leukaemia clones by Tax-targeted dendritic cell vaccine.
由DC疫苗介导的正常T细胞免疫的恢复可能有助于这种持久缓解。
一项Tax肽脉冲树突状细胞（DC）疫苗用于成人T细胞白血病/淋巴瘤（ATL）的初步临床研究显示了良好的临床结局。
我们通过T细胞受体（TCR）库分析，对一名入组ATL患者在接受DC疫苗后实现10年完全缓解的样本，研究了其抗肿瘤效果。
在该患者中，先前治疗后持续存在的优势残留ATL克隆在DC疫苗接种后3年内完全消失。此外，DC疫苗恢复了正常T细胞的TCR库多样性，并新诱导了功能性Tax特异性CD8+ T细胞克隆。
BACKGROUND: A pilot clinical study of a Tax peptide-pulsed dendritic cell (DC) vaccine for adult T-cell leukaemia/lymphoma (ATL) indicated favourable clinical outcomes. METHODS: We investigated its anti-tumour effect by T cell receptor (TCR) repertoire analysis in samples from an enrolled ATL patient who achieved a 10-year complete remission after DC vaccination. RESULTS: In this patient, the dominant residual ATL clones that had persisted following previous treatment entirely disappeared within 3 years after DC vaccination. Additionally, the DC vaccine restored TCR repertoire diversity of normal T cells and newly induced functional Tax-specific CD8 + T cell clones. CONCLUSIONS: The recovery of normal T cell immunity mediated by the DC vaccine may contribute to this long-lasting remission.
MEMBER ACCOUNT
登录成功会直接打开下一页。
